Tag : EnvericBiosciences

CCT Impact

Enveric Biosciences and MagicMed to Participate in June 2021 Investor and Industry Conferences

CCT IMPACT Agent
Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a patient-first biotechnology company developing novel naturally occurring medicines to improve quality of life for cancer patients, and MagicMed Industries (“MagicMed”), a privately-held biotechnology company focused on creating a library of novel derivative psychedelic molecules such as psilocybin, N,N-dimethyltryptamine (DMT) and other molecular derivatives with applications......
CCT Impact

Enveric Biosciences Reports Full Year 2020 Financial Results and Provides Shareholder Update on its Accomplishments in 2021

CCT IMPACT Agent
Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a patient-first biotechnology company developing novel cannabinoid (CBD)_medicines to improve quality of life for cancer patients, today reported its financial results for the year ended December 31, 2020 and provided shareholders with an update on its accomplishments in 2021 thus far. David Johnson, Chairman and......
CCT Impact

Enveric Biosciences to Participate in Upcoming Investor Conferences in March

CCT IMPACT Agent
Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a patient-first biotechnology company developing novel cannabinoid medicines to improve quality of life for cancer patients, today announced that David Johnson, Chairman and Chief Executive Officer, will participate in two upcoming investor conferences in March: M Vest and Maxim Group Inaugural Emerging Growth Conference to......